If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 31

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer, Other Skin, Bladder, Colorectal, Cervix, Other Gynecologic, Breast Cancers, Esophagus, Prostate, Larynx, Other Gastrointestinal, Esophagus, Gynecologic Cancers, Other Respiratory, Melanoma, Skin, Prostate and Urologic Cancers, Pancreas/Liver, Eye/Orbital Cancers, Thoracic Cancers, Lip, Oral Cavity and Pharynx, Head and Neck Cancers, Gastrointestinal Cancers, Endocrine Cancers, Skin Cancers, Brain and Spine Cancers

REMASTer: REcurrent Brain Metastases After SRS Trial

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer, Stomach, Prostate, Breast Cancers, Other Skin, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Head and Neck Cancers, Thoracic Cancers, Sarcoma, Other Urologic, Pancreas/Liver, Cervix, Gynecologic Cancers, Esophagus, Melanoma, Skin, Bladder, Gastrointestinal Cancers, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol

Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Categories
Cancer, Bladder, Lung, Cervix, Lip, Oral Cavity and Pharynx, Gastrointestinal Cancers, Other Skin, Larynx, Kidney, Melanoma, Skin, Gynecologic Cancers, Thoracic Cancers, Skin Cancers, Breast Cancers, Head and Neck Cancers, Prostate and Urologic Cancers